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Abstract
Introduction Genomic alterations have been observed in breast
carcinomas that affect the capacity of cells to regulate
proliferation, signaling, and metastasis. Re-sequence studies
have investigated candidate genes based on prior genetic
observations (changes in copy number or regions of genetic
instability) or other laboratory observations and have defined
critical somatic mutations in genes such as TP53 and PIK3CA.
Methods We have extended the paradigm and analyzed 21
genes primarily identified by expression profiling studies, which
are useful for breast cancer subtyping and prognosis. This study
conducted a bidirectional re-sequence analysis of all exons and
5', 3', and evolutionarily conserved regions (spanning more than
16 megabases) in 91 breast tumor samples.
Results Eighty-seven unique somatic alterations were identified
in 16 genes. Seventy-eight were single base pair alterations, of
which 23 were missense mutations; 55 were distributed across
conserved intronic regions or the 5' and 3' regions. There were
nine insertion/deletions. Because there is no a priori way to
predict whether any one of the identified synonymous and
noncoding somatic alterations disrupt function, analysis unique
to each gene will be required to establish whether it is a tumor
suppressor gene or whether there is no effect. In five genes, no
somatic alterations were observed.
Conclusion The study confirms the value of re-sequence
analysis in cancer gene discovery and underscores the
importance of characterizing somatic alterations across genes
that are related not only by function, or functional pathways, but
also based upon expression patterns.
Introduction
Somatic mutations in key genes, such as oncogenes and
tumor suppressor genes, have been reported to contribute to
the risk for development of many human cancers. Genomic
alteration has been shown to confer altered capacity for cell
proliferation, metastasis, and responsiveness to either normal
cellular signals or therapeutic agents [1]. Advances in
sequence technology have lead to renewed efforts in the dis-
covery and characterization of somatic mutations in different
cancers. This avenue of investigation has emerged as a prom-
ising approach to dissect the profile of genetic alterations of
cancer in order to better classify cancer subtypes, identify new
mechanisms of carcinogenesis, and characterize possible
biomarkers for susceptibility and outcome [2,3]. In fact, it isPage 1 of 9
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genomes will be pursued in the future, because of the conflu-
ence of two major trends, the availability of complete human
genome sequences, and advances in sequencing technology
and analysis. Although very promising, this approach is yet to
be fully developed but has been fueled in part by the charac-
terization of somatic sequence alterations in candidate gene
studies of specific cancers, such as breast and colon cancer.
Because it is still a formidable task to sequence entire
genomes, investigators have analyzed individual candidate
genes chosen based on results of previous studies in cell
lines, animal models, or other primary human tumors. Initial re-
sequence studies examined individual candidate genes based
on prior genetic observations (changes in copy number or
regions of genetic instability) or those identified in animal or in
vitro laboratory studies and have defined critical somatic muta-
tions in genes such as TP53 and PIK3CA [4-11]. To date,
most studies have concentrated on coding regions and the
adjacent intronic region, in search of mutations that alter the
coding sequence or RNA splicing. Selected studies have
extended the choice of candidate genes to include a complete
gene family, such as the protein kinase family or tyrosine phos-
phatome [2,3,12-14]. Concentrated investigation in the pro-
tein kinase genes has been conducted because of prior
evidence that selected genes, such as PIK3CA, are frequently
mutated in breast cancer [7-11]. Stephens and coworkers
[15] reported on the re-sequence analysis of the coding region
of 518 protein kinase genes in breast, lung, and testicular can-
cer. Recently, Sjoblom and colleagues [16] surveyed somatic
alterations in 13,023 genes in 11 breast and 11 colon cancer
cell lines or xenografts.
The success of the candidate gene approach has provided the
impetus for this study to re-sequence 21 genes chosen mainly
based upon expression profiling studies. These genes vary in
expression across breast carcinoma samples and have been
shown to be useful for breast cancer subtyping and prognosis
[17-19]. Overall, copy number of the genes was not changed
in the breast tumors, as assessed by array-based comparative
genomic hybridization analyses [20]. Herein, we report the re-
sequence analysis in 91 primary breast tumors of coding and
noncoding regions of genes drawn from a novel paradigm,
which was to select genes that have an altered expression pat-
tern across breast carcinomas.
Materials and methods
DNA sampling and sequence analysis
Genomic DNA from 91 tumor samples were included in this
study, of which 82 were from Norwegian breast cancer cases
and nine were from a new breast cancer study in North Caro-
lina. The Norwegian breast cancer samples were selected
from a series of 215 previously published primary breast can-
cer samples, of which 63 of the 82 included in this study have
been analyzed using cDNA microarrays (Langerod and cow-
orkers, unpublished data). Patient tissue samples were
sequentially collected at Ullevål University Hospital from 1990
to 1994 under an institutional review board approved protocol.
Primary breast carcinoma tissue was snap frozen and stored
at -80°C. Frozen sections stained with hematoxylin/eosin were
reviewed to confirm tumor content. More than 80% of the sam-
ples analyzed had more than 40% tumor cell content. Blood
samples were collected in EDTA tubes and frozen at -40°C
before DNA was isolated. DNA was extracted from both
peripheral blood cells and tumor tissue using a method of
chloroform/phenol extraction followed by ethanol precipitation
(Nuclear Acid Extractor 340A; Applied Biosystems, Foster
City, CA, USA), according to standard procedures. Matched
control genomic DNA was available from peripheral blood
from 36 of the Norwegian breast cancer cases.
Of the set of 21 genes selected for this re-sequencing analy-
sis, 13 of them (FZD7, NQO1, MYBL2, PLK1, STK6, ESR1,
FOXA1, FOXC1, GATA3, RARRES3, RERG, XBP1, and
CDK5) were selected primarily based on their variation in
gene expression patterns from previous studies of breast car-
cinomas [17,18] and eight were selected based on previous
reports that they harbor somatic mutation in breast cancers
(CAV1, CDH1, FBXW7, PIM1, PIN1, TP53, TP53I3, and
RB1CC1), although they showed considerable variation in
expression patterns (Figure 1 and Additional file 1).
Sequencing primers were designed for bidirectional sequence
analysis using Primer3 software [21]. Each oligonucleotide
was extended with a universal sequencing primer: M13 for-
ward (TGTAAAACGACGGCCAGT) or M13 reverse (CAG-
GAAACAGCTATGACC). Primers and conditions are posted
on the SNP500 Cancer website [22]. Standard cycle
sequence analysis was performed (MJ Research PTC-200
Thermacycler) (MJ Sciences Waltham, MA, USA). Polymerase
chain reaction (PCR) products were cleaned up with Exonu-
clease I/Shrimp Alkaline Phosphatase (USB, Cleveland, OH,
USA). PCR products were sequenced using a modified ABI
Prism® BigDye Terminator protocol (ABI, Foster City, CA,
USA). Pgem®-3Zf(+) (Promega Corp., Madison, WI, USA)
was used for controls in all sequencing reactions. The
sequencing reactions were cleaned up by either Sephadex G-
50 (Sigma, St Louis, MO, USA) spin columns in a Multi-
Screen®-HV 96-well filter plate (Millipore, Billerica, MA, USA)
or Performa® DTR 384-well spin plate (Edge BioSystems,
Gaithersburg, MD, USA). The reactions were run on either ABI
3700 or ABI 3730XL (ABI). Sequence traces were reviewed
by two independent reviewers.
Bidirectional sequence analysis included 166 exons (62,000
bp) and an additional 120,000 bp of noncoding sequence in
tumor samples from the 91 cases of breast cancer. In each
gene, sequence analysis targeted at least 2 to 3 kb upstream
of the first exon and 2 kb downstream of the 3'-untranslatedPage 2 of 9
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(defined as 75% or greater sequence similarity over a 200 bp
fragment for alignment of mouse and human sequence) [23].
For each amplicon in which a sequence variant was observed
in a tumor sample, sequence analysis was also performed in
the SNP500 Cancer reference set of 102 individuals drawn
from the four major ethnic groups of the USA and a set of 94
anonymized Norwegian women who were older than 55 years
and had a history of two negative mammograms [24].
We estimated the mutation rate based on the number of
somatic events observed divided by the total number of base
pairs sequenced in the analysis. This calculation combines
potentially functional mutations (for example, driver mutations)
with passenger somatic alterations [15].
Hierarchical clustering analysis
A total of 194 breast tumors were analyzed by clustering anal-
ysis using a modified version of the 'SAM264' gene list [18];
the 'SAM264' gene set is the set of genes that were associ-
ated with survival as identified using a Significance Analysis of
Microarray analysis and contained 10 of the 21 genes
sequenced. We added the 11 remaining re-sequenced genes
to the SAM264 list for clustering analysis. Initially, we created
a single sample set that was a combined dataset of the previ-
ous 122 samples [18,19], and 63 tumors from Langerod and
coworkers (unpublished data) and nine tumors from North
Carolina that included most of the samples used for the rese-
quencing analysis presented here. This combined sample set
was used to guide gene selection for resequencing analyses.
Because these three sets of samples were assayed using dif-
ferent microarrays, the two-color cDNA microarray datasets
[18,19] (Langerod and coworkers; unpublished data) and the
nine Agilent A1 microarray experiments performed at Univer-
sity of North Carolina, they were pre-processed similarly and
systematic array biases removed using distance weighted dis-
crimination (DWD) [25]. First, gene annotation from each
dataset was translated to UniGene Cluster IDs (Build #185)
using the SOURCE database [26]. The pre-processing
included an initial selection for genes that exhibited a signal
intensity of greater than 30 units in both the Cy3 and Cy5
channels across at least 70% of the experiments, which
caused FBXW7 and PIN1 to be removed from further analy-
ses because of very low signal intensities. Next, we log2 trans-
formed the R/G ratio and then Lowess normalized the data
Figure 1
Hierarchical clustering analysis of 194 breast tumor samples analyzed using the 'SAM264' patient survival associated gene set augmented with nine additional gene  included in the resequencing analy is
additional genes included in the resequencing analysis. (a) Hierarchical clustering overview that shows the overall context for the 21 genes. (b) 
Close up of the sample associated dendrogram, which identifies the tumor samples that were re-sequenced in red. (c) Luminal/ER+ epithelial gene 
set showing coordinated expression of ESR1, GATA3, FOXA1, and XBP1. (d) Proliferation gene set showing expression of STK6, MYBL2, and 
PLK1. (e) Basal epithelial gene set showing the expression of FOXC1 and FZD7. (f) The expression profiles of the additional genes that were re-
sequenced but that did not fall into the previous expression patterns are shown, and their position in the larger cluster is also shown in panel a. All 
genes identified in red text were analyzed by re-sequencing in this study, and only FBXW7 and PIN1 were not included in this cluster analysis 
because their average expression levels did not meet the gene filtering criteria. ER, estrogen receptor.Page 3 of 9
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algorithm (k = 10) described by Troyanskaya and coworkers
[28]. The expression values for duplicated probes with the
same Unigene cluster ID were collapsed using the median
expression value. DWD was performed in a pairwise manner
by first combining the dataset reported by Sørlie and cowork-
ers [18] with that by Langerd and coworkers (unpublished
data), and subsequently combining this with the University of
North Carolina data. In the final step of pre-processing, each
individual experiment (microarray) was normalized by setting
the mean to zero and its standard deviation to one, and each
gene was median centered. The DWD corrected data for the
SAM264 genes plus nine additional genes was finally used in
a two-way average linkage hierarchical cluster analysis using
centered correlation across the 194 microarrays.
Results
In total, more than 16.2 megabases were sequenced and
more than 95% of the targeted amplicons were analyzed.
Eighty-seven unique somatic nucleotide variants were identi-
fied in 16 genes (TP53, GATA3, CAV1, CDH1, ESR1,
FBXW7, FOXA1, FOXC1, FZD7, MYBL2, PIN1, RB1CC1,
RERG, STK6, TP53I3, and XBP1; see Table 1 and Additional
file 2 for detailed results for each sample). In five genes
(CDK5, NQO1, PLK1, PIM1, and RARRES3) no somatic
sequence alterations were observed. The majority of
sequence alterations were observed once, although there
were three missense mutations that were observed more than
once. The distribution of the somatic alterations per tumor
sample is shown in Figure 2. Fifty-three tumors had one or
more somatic alteration, and in 38 tumor samples (42%) no
somatic alterations were noted. The largest number of somatic
alterations observed was seven in one sample, but these were
distributed over four separate genes. The overall distribution of
the single base pair somatic alterations favored transitions
over transversions (50 versus 28).
Of the 87 total somatic alterations observed, 78 single base
pair somatic alterations were distributed across 16 of the 21
genes analyzed (Table 1). For the purposes of this analysis, a
single base pair somatic alteration was defined on the basis
that it was observed in a tumor specimen but not in the consti-
tutional DNA of 102 controls from the SNP500 Cancer set, or
matched blood DNA of 36 of the Norwegian breast cancer
cases. Of the 78 single pair somatic alterations, we observed
34 alterations in coding regions; 23 were missense alterations
and 11 were predicted to be synonymous changes (for exam-
ple, no alteration of the predicted amino acid). In noncoding
regions, 44 single base pair somatic alterations were
observed, of which 27 were in evolutionarily conserved
intronic regions, 12 in the analyzed 5' region, and five in the
analyzed 3' region.
Sequence analysis of the tumor samples identified 252 single
nucleotide polymorphisms (SNPs), all of which were con-
firmed in blood samples drawn from 94 Norwegian women
with no history of breast cancer and the reference SNP500
Cancer set [22].
We observed 23 missense mutations in eight of the 21 genes
studied. TP53 and GATA3 were notable because of the large
number of sequence alterations observed, which included
missense mutations and insertion/deletions previously
reported [4-6,29]; in total, there were 14 distinct missense
mutations, one pre-terminal stop codon, four insertion/dele-
tions, and five noncoding alterations. For both of these genes,
the majority of sequence variants have been shown to be func-
tionally significant somatic mutations, and thus could be con-
sidered as 'driver' mutations for oncogenesis [15]. Eight novel
missense alterations were found in six additional genes
(CDH1, FBWX7, ESR1, RB1CC1, TP53I3, and XBP1). Of
the eight missense alterations, two were observed in CDH1
and two in ESR1, and four overall resulted in significant amino
acid shifts by Miyata criteria [30]. In RB1CC1, a significant
amino acid shift is predicted, namely R1514C, with a high Miy-
ata score of 3.06; this results in a positively charged residue
being changed to a hydrophilic residue. The mutation M180K
in TP53I3 has a Miyata score of 2.63 and predicts a change
from a hydrophobic to a positively charged residue. In ESR1,
a H6Y with a Miyata score of 2.27 predicts a shift of a positive
charge to a hydrophilic charge. In the FBXW7 gene, the
E117K substitution with a Miyata score of 1.14 results in a
shift from negative to positive charge. There are several con-
servative substitutions that have low Miyata scores: in the
CDH1 gene the M282I variant was observed twice and gave
a Miyata score of 0.29, and the D777N variant has a Miyata
score of 0.65; in ESR1 the M264I variant has a score of 0.29;
and in XBP1 the variant R232K has a Miyata score of 0.4.
In FZD7, we observed two synonymous variants, L23L and
L26L, which are both in close proximity to a common SNP in
codon 24 that results in a conservative shift from glycine to
arginine. Notably, a second SNP that also affects codon 24,
namely G24S, was seen in the Norwegian population, which
also results in a conservative shift with a Miyata score of 0.85.
These data suggest that this could be a region of increased
mutational activity, but further work on breast tumors and cell
lines is needed to characterize the functional implications of
the changes. The distribution of alterations did not differ from
that of the SNPs across the same regions for both coding and
noncoding regions.
Insertion/deletion somatic alterations were observed in four
genes, and there were a total of nine. Six were insertion/dele-
tion alternations within the coding region of the gene and one,
a 4 bp insertion, occurred at the splice site junction in CDH1.
The gene most frequently observed with insertion/deletion
(four) was CDH1, which has previously been reported to have
altered copy number (loss of heterozygosity), and can undergo
somatic mutation and silencing by methylation [31-33]. Muta-Page 4 of 9
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more frequently in the lobular histologic subtype [34], and in
our series two out of three with frameshift somatic alterations
were observed in tumors classified as lobular.
Of the 21 genes included in the re-sequencing analysis, 10 of
the 21 were contained within the 'SAM264' set of genes,
which represents genes that were associated with breast can-
cer patient survival times [17]. In order to visualize the expres-
sion patterns of all the re-sequenced genes, we added the 10
missing genes (CDH1, CAV1, FBXW7, PIM1, PIN1, TP53,
TP53I3, RB1CC1, FZD7, and CDK5) to the SAM264 gene
set and performed a hierarchical clustering analysis using a
dataset of 194 tumors, which was the combined data on the
tumors used to select genes for re-sequencing analysis
[18,19] and 72 of the tumors that were actually re-sequenced
(Figure 1). After standard data quality gene filtering methods
were employed, 19 out of 21 genes were present (FBXW7
and PIN1 gave very low signal intensities) in the clustering
analysis and clearly exhibited significant variation in expression
Table 1
Somatic alterations by region in breast cancer re-sequence analysis
Gene Nonsynonymous Synonymous 5' IVS 3' Indel
TP53a R110P, F113V, A138V (2), Y163C, Y163H, H193T, 
I195T, V216M, S241A, R249M, I251S, D259Y, 
R273C (3)
IVS1+75A>G
IVS6-2A>G
IVS7-1G>T
7 bp @ G286
22 bp @ L189
GATA3a R366X, R366L IVS2-281C>G Ex5+311C>G CA @ IVS3-3
A @ T315
CAV1 D143D -2768A>C
-1446T>A
-596A>G
Ex3-3G>C
CDH1 D777N
M282I (2)
A563A IVS3+128T>C
IVS3+260A>G
IVS7+47T>C
IVS7+2049T>A
IVS8-175G>A
CCGG @ Ex3+19
A @ Ex345
G @ Ex7+15
AAGT @ IVS13+3
ESR1 H6Y
M264I
Ex1+139G>C Ex8+2144T>A
FBXW7 E117K IVS1-1641A>C
FOXA1 -3717G>A
FOXC1 -2713G>T
-1770C>T
+936G>A
+940G>A
FZD7 L23L
L26L
G409G
-1387G>C
MYBL2 IVS7+15A>G
IVS8-14C>G
IVS12+28G>C
PIN1 S38S IVS2+3447G>A
IVS2+3419G>A
IVS2+3370T>C
RB1CC1 R1514C S1424S
L1511L
-31467C>A
-30224C>G
IVS1+5248T>G
IVS1+6068A>G
IVS11+97T>C
IVS11-36C>T
IVS15+1535C>G
IVS21-16G>A
RERG Ex1+63G>T IVS2+27438T>G
IVS2-30415C>T
CTTdel @ IVS2-7163
STK6b A172A
E175E
IVS4-35A>G
IVS9-33A>G
TP53I3 M180K P102P
XBP1 R232K -2339G>C IVS4-11G>A
Eighty-seven unique somatic alterations were identified by sequence analysis in 16 of 21 genes analyzed (TP53, GATA3, CAV1, CDH1, ESR1, 
FBXW7, FOXA1, FOXC1, FZD7, MYBL2, PIN1, RB1CC1, RERG, STK6, TP53I3, and XBP1). No somatic alterations were detected in five 
genes (CDK5, NQO1, PIM1, PLK1, and RARRES3). All alterations were observed singly in bidirectional sequence analysis; numbers in 
parentheses indicates the number of unique tumor samples with somatic alterations. Intronic analysis restricted to regions including 100 bp on 
either side of exonic junctions and evolutionarily conserved regions between mouse and human (>75% similarity over 200 bp). aMost of the 
nonsynonymous mutations and deletions in TP53 and GATA3 were previously reported [4,19]. bIn the analysis of STK6 (also known as STK15), 
additional alterations were observed at six sites within the target 5' region but lie in the adjacent gene CSTF1 (-7698C>T, -7648A>G, -7105C>T, 
-5992A>G, -4868A>G, and -4221G>A). None of the variants result in nonsynonymous alterations in the coding region of CSTF.Page 5 of 9
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using the modified SAM264 list and just the 63 Norwegian
samples that were included in the re-sequencing was also per-
formed (Additional file 1), and in this analysis the differential
expression of the genes over this set of tumor samples reca-
pitulated our previous findings and showed that many of the
re-sequenced genes have expression patterns that define the
breast tumor subtypes [18,19].
Discussion
We report the results of a re-sequence analysis of 21 candi-
date genes in 91 primary breast tumors. The candidate genes
were chosen mainly based upon previous expression profiling
studies and the target sequencing regions were extended
beyond coding regions to include evolutionarily conserved
regions and the 5' and 3' regions. This latter point is essential
because it underscores the importance of examining genetic
regions that could alter the expression or stability of a gene.
Our results identified a spectrum of single base sequence
alterations in 16 of the 21 genes selected for targeted re-
sequence analysis.
Unlike the report by Stephens and coworkers [15], we did not
observe clustering of sequence alterations in a single tumor.
The maximum number of alterations in any of the 21 genes
observed in a single tumor was seven, and we observed no
somatic alteration in nearly 40% of the samples analyzed. We
can exclude the likelihood that loss of heterozygosity could
account for this, because the density of common SNPs
observed across the 21 genes was comparable to the density
observed in the SNP500 Cancer set and the International
HapMap study [35]. We observed a comparable ratio for tran-
sitions to transversions to that reported by Stephens and col-
leagues [15].
In our analysis we observed 27 total somatic alterations muta-
tions in eight of the 21 genes studied, and of these 23 were
unique missense alterations. In contrast, there were 11 synon-
ymous alterations. The difference in the observed number of
nonsynonymous changes relative to synonymous SNPs did
not deviate significantly from expected [36]. Unlike the study
conducted by Stephens and coworkers [15], we did not
observe enrichment of nonsynonymous changes relative to
synonymous changes in our set of 21 genes chosen on the
basis of expression profiles.
Wide variance in the number of somatic alterations per gene
was observed, which did not always correlate with previous
reports. For instance, in the RB1CC1 gene, which was previ-
ously reported to undergo truncating mutations in breast
tumors [37], our bidirectional sequence analysis revealed
eight noncoding alterations, two synonymous alterations, and
a single nonsynonymous change, namely R1514C (Miyata
score of 3.06), which results in a positively charged residue
shift to a hydrophilic residue. In PIN1, a gene previously
reported to be mutated in breast cancer [38], we observed
only one synonymous nucleotide change. Interestingly, two
alterations were observed in FBXW7, namely a nonsynony-
mous E117K with a significant amino acid shift and an intronic
alteration; this is in contrast to previous reports [39,40], which
found a higher rate of mutation in FBXW7 in breast cancer cell
lines.
Our approach differed from the prior reported studies in that
the re-sequence analysis also targeted regions of possible
regulatory importance. In fact, our study targeted sequence in
contiguous noncoding regions, which could be enriched for
regulatory regions to be defined functionally. Because there is
no a priori way to predict whether any one of the identified syn-
Figure 2
Distribution of samples with observed number of somatic alterations. Total number of somatic alterations per sample are included underneath the 
bars and the total number of samples in each category is represented on the vertical axis.Page 6 of 9
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analysis unique to each gene will be required to establish
whether the change is functional. At this time, we interpret the
majority of these changes to be nonfunctional and perhaps
related to an increase in background mutation rate in cancer,
specifically in breast cancer. In this regard, we confirmed the
findings of Stephens and coworkers [15] that the majority of
observed somatic variants are probably passenger or hitchhik-
ing mutations and not necessarily subject to selection. Further
laboratory work is needed to determine which sequence alter-
ations bear functional consequences for the development of
breast cancers.
It is notable that we observed somatic alterations in genes not
observed in the study conducted by Sjoblom and coworkers
[16] (for instance, ESR1, GATA3, and CDH1). This is not sur-
prising because our study included a large number of estrogen
receptor positive and estrogen receptor negative samples in
our SNP discovery phase. Moreover, GATA3 and ESR1 muta-
tions appear to be mutated primarily in estrogen receptor pos-
itive tumors, which were not included in the discovery cell line
set used in the study conducted by Sjoblom and colleagues
[29].
The prevalence of somatic mutations probably varies between
different cancers and possibly by populations [2,3,14,15].
Previous surveys of the coding regions in colon and breast
cancer were biased toward genes of the protein kinase family
and reported a rate of approximately one somatic alteration per
megabase of sequence. We estimate that the rate of somatic
mutation in genes altered in expression pattern in breast can-
cer is slightly higher than that reported for colon cancer and
breast cancer [2,3,12]. Based on this survey of coding and
noncoding sequence (at a ratio of 1:3) for 21 genes, we esti-
mate the rate of somatic alteration could be as high as 5.3 per
megabase, but this assumes that all variants are indeed
somatic variants. It is possible that a subset could be rare
germline variants. Thus, our estimate for the somatic mutation
rate in breast cancer is slightly higher than the previous reports
of approximately 1.2 nonsynonymous somatic changes per
megabase in colon cancer [2,3,15]. We also note that two-
thirds of the sequence analyzed in the present study is non-
coding. An estimate of the rate of somatic alterations did not
differ between noncoding and coding regions, suggesting that
the majority could be hitchhiking mutations. In an analysis of
11 breast cancer cell lines and colon tumor xenografts, Sjob-
lom and coworkers [16] also observed more somatic altera-
tions, approximately 2.5 more, than in the earlier studies
[2,3,15]. Together with our results, these data suggest that
somatic alterations could arise more frequently than was orig-
inally reported. It is also notable that our study also targeted
noncoding regions, where somatic alterations rates might dif-
fer from those in coding regions. Further studies are required
to address this important point.
It is plausible that our study might also underestimate the rate
of somatic alteration because we previously identified five
additional mutations in the TP53 gene [6] (Langerod and cow-
orkers, unpublished data) in the Norwegian tumor samples
using a highly sensitive screening technique, namely temporal
temperature gel electrophoresis (TTGE), prior to sequencing
(these mutations are marked in Additional file 2). This pre-
screening allowed us to detect mutations in a heterogeneous
tumor sample with as low as 1% mutated cells [41], and aber-
rant migrating band on the TTGE gel can be sequenced
directly to define the sequence alteration. Microdissection
before sequencing will not fully avert this problem because of
tumor heterogeneity. To use TTGE as pre-screening is imprac-
tical because it is labor intensive to establish and not easily
amenable to high throughput analyses. Because we had pre-
viously performed TTGE for TP53 analyses, we were able to
assess the sensitivity of the different techniques; both tech-
niques failed to identify all mutations.
Conclusion
Systematic re-sequence analysis of a sufficiently large set of
tumor samples drawn from well designed clinical and epidemi-
ologic studies promises to identify new cancer associated
genes and somatic mutations that are linked to response to
cancer therapy [42-44]. The present study confirms the value
of re-sequence analysis in cancer gene discovery and
underscores the importance of characterizing somatic altera-
tions across genes related not only by function, or functional
pathways, but also based upon expression patterns. Advances
in sequencing technology will certainly accelerate the charac-
terization of somatic alterations in the cancer genome, but the
task of defining the importance of observed somatic changes
will continue to rest on the shoulders of future laboratory
investigators.
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